NCT02845882 2026-03-18
LBL-2016 for Children or Adolescents in China
Children's Cancer Group, China
Phase 3 Active not recruiting
Clinical Trials
41 trialsNCT06773936 2026-03-04
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Enrolling by invitation
NCT04542824 2026-03-03
EPCORE™ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT07029776 2026-03-03
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
University of Arkansas
Phase 2 Not yet recruiting
NCT07407140 2026-03-02
VAG-3+7-G
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT06587451 2026-02-24
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Sandoz
Phase 3 Terminated
NCT07405736 2026-02-12
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06656598 2026-02-11
SPORADIC
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Recruiting
NCT07372365 2026-01-28
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT07207824 2025-10-06
HERO
Fudan University
Phase 3 Not yet recruiting
NCT07199855 2025-09-30
Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia
Zhejiang University
Phase 2 Active not recruiting
NCT05051631 2025-08-28
BRAVE
Vanderbilt University Medical Center
Phase NA Completed
NCT07014202 2025-07-30
Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT07094464 2025-07-30
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
Chinese PLA General Hospital
Phase 1 Active not recruiting
NCT05827549 2025-06-06
ReCALL
Asan Medical Center
Phase 2 Recruiting
NCT03690869 2025-04-08
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT05375708 2025-03-28
SIRIUS
UMC Utrecht
Phase 2 Suspended
NCT06827353 2025-02-14
OVNI-B
Centre Hospitalier Universitaire de Nīmes
Recruiting
NCT06744894 2024-12-20
SIL as Maintenance Therapy in Multiple Myeloma
Navy General Hospital, Beijing
Phase 2 Not yet recruiting
NCT06714084 2024-12-03
CNCMT
Hubei Cancer Hospital
Phase NA Enrolling by invitation
NCT06503263 2024-09-19
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Navy General Hospital, Beijing
Phase 2 Recruiting
NCT06341556 2024-09-04
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Fudan University
Phase 2 Recruiting
NCT06277050 2024-04-30
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital
Phase 3 Recruiting
NCT00777998 2023-10-27
Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Completed
NCT02396043 2023-06-18
Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT05641870 2022-12-12
Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC
Parc de Salut Mar
Unknown
NCT02063685 2022-06-21
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
Phase 3 Completed
NCT03983226 2022-03-18
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Shanghai Gynecologic Oncology Group
Phase 2 Recruiting
NCT02027428 2020-08-17
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Celgene
Phase 3 Completed
NCT03847727 2020-01-18
Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia
Pirogov Russian National Research Medical University
Unknown
NCT04008888 2019-07-05
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Unknown
NCT01554852 2018-06-11
Myeloma XI
University of Leeds
Phase 3 Unknown
NCT03489616 2018-04-05
CRAGMOLC
Shandong Cancer Hospital and Institute
Phase NA Unknown
NCT02919462 2018-01-16
HighTySy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT02858258 2017-12-19
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
European Mantle Cell Lymphoma Network
Phase 3 Recruiting
NCT00580372 2016-09-20
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
University of Arkansas
Phase 2 Completed
NCT02296398 2016-03-11
Long-term Use of Romidepsin in Patients With CTCL
Northwestern University
Completed
NCT00480363 2013-07-31
QUIREDEX
PETHEMA Foundation
Phase 3 Completed
NCT01665001 2012-08-17
Personalized Therapy of Precursor Lymphoid Neoplasms
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Phase 2 Unknown
NCT00560053 2008-11-27
Pethema Multiple Myeloma 2000
PETHEMA Foundation
Phase 3 Completed
NCT00599937 2008-01-24
APL93: Timing of CxT and Role of Maintenance
Groupe d'etude et de travail sur les leucemies aigues promyelocytaires
Phase 3 Completed